about
Immature monocyte derived dendritic cells gene expression profile in response to Virus-Like Particles stimulation.Systems Biology Approach for Cancer Vaccine Development and EvaluationDevelopment of a stable insect cell line constitutively expressing rotavirus VP2.Functional characterization of biodegradable nanoparticles as antigen delivery system.Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculationHIV p24 as scaffold for presenting conformational HIV Env antigens.Genetic and phylogenetic evolution of HIV-1 in a low subtype heterogeneity epidemic: the Italian exampleEffects of adjuvants on IgG subclasses elicited by virus-like particles.Immunogenicity of HIV virus-like particles in rhesus macaques by intranasal administration.A novel multi-drug metronomic chemotherapy significantly delays tumor growth in mice.Molecular and phylogenetic analysis of HIV-1 variants circulating in ItalyCharacterization of humoral responses to soluble trimeric HIV gp140 from a clade A Ugandan field isolateIdentification and Validation of HCC-specific Gene Transcriptional Signature for Tumor Antigen Discovery.Conformational HIV-1 envelope on particulate structures: a tool for chemokine coreceptor binding studies.Developments in virus-like particle-based vaccines for infectious diseases and cancer.Developments in virus-like particle-based vaccines for HIV.Challenges in cancer vaccine development for hepatocellular carcinoma.Systems vaccinology for cancer vaccine development.Antigen-specific vaccines for cancer treatment.Cellular prognostic markers in hepatocellular carcinoma.Combinatorial immunotherapy strategies for hepatocellular carcinoma.HIV type 1 subtype A epidemic in injecting drug user (IDU) communities in Iran.Baculovirus-derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses.Evaluation of a modified version of Heteroduplex Mobility Assay for rapid screening of HIV-1 isolates in epidemics characterized by mono/dual clade predominance.Formation of self-assembled triple-layered rotavirus-like particles (tlRLPs) by constitutive co-expression of VP2, VP6, and VP7 in stably transfected high-five insect cell lines.Immunological effects of a novel RNA-based adjuvant in liver cancer patients.HIV-Gag VLPs presenting trimeric HIV-1 gp140 spikes constitutively expressed in stable double transfected insect cell line.Constitutive expression of HIV-VLPs in stably transfected insect cell line for efficient delivery system.Novel metronomic chemotherapy and cancer vaccine combinatorial strategy for hepatocellular carcinoma in a mouse model.Prediction of individual immune responsiveness to a candidate vaccine by a systems vaccinology approach.Can HIV p24 be a suitable scaffold for presenting Env antigens?Generation of HIV-1 Virus-Like Particles expressing different HIV-1 glycoproteins.Human papillomavirus infection in urine samples from male renal transplant patients.P19-11. Generation of virus-like particles expressing different HIV-1 glycoproteins for induction of broadly neutralizing antibodies.P12-03. Generation of novel recombinant HIV-1 glycoproteins for expression on virus like particles.Genetic and phylogenetic characterization of structural genes from non-B HIV-1 subtypes in ItalyScreening of HIV-1 Isolates by Reverse Heteroduplex Mobility Assay and Identification of Non-B Subtypes in ItalyVirus-Like ParticlesDevelopments in virus-like particle-based vaccines for HIVCorrigendum to: “Challenges in cancer vaccine development for hepatocellular carcinoma” [J Hepatol 2013;59:897–903]
P50
Q25257050-8A853484-9FC8-4347-9171-034CF9010C92Q26782580-5BEB1339-5461-4DF6-935F-7C21345B16D0Q30425503-93EAEF3B-F51F-42F3-A56C-C392EF0BCBD1Q30667121-57335025-34B2-4942-A9FA-67364480F606Q33788701-21BC38F2-CA28-4D92-91CA-3FAA7B9CD13FQ34389522-EB520648-5141-4876-9AD6-4D506C3E93F4Q35843775-7D17FCEA-21E4-46BF-8555-85082FB37D1CQ35848642-1031C918-5B89-40EF-9F24-00865A389C72Q36017750-3AE4B3F8-8481-412F-ACF1-025D6A8C7AEAQ36616446-3E7BFF9B-467C-4BD0-BCD9-48E29885DE69Q36981930-043EB054-BC56-4739-AFC3-8EB767CD26E3Q37060319-F0A0677F-EEEA-4F9E-88FB-AD785C956A0CQ37076019-AC6CC6FC-46C4-4101-811A-0DFAA8AF9933Q37834097-28B4759C-B9F0-44D8-8C42-E9AD9C4FF922Q37951525-6E050C28-8171-47A1-B558-10EBF7F7661CQ38081965-31AD0C0C-0C1D-4A83-9987-4EC21B20258AQ38109956-4B1BD376-18CD-4273-B6B2-EAF78E426581Q38207141-80F883A8-2B56-4ADD-B840-94070D45E242Q38284692-9F46D626-28FB-4553-A65E-F79047F839B7Q38515812-C61906A2-36A8-43AC-93AC-9029F92241A6Q38724917-F4F23FB2-C1AF-438F-BB48-81EB11AF3E2CQ38876929-547AB171-AF34-46D6-B6AC-39AB1D1088A9Q38879108-C850A0F8-6F06-4B65-95A8-AE3C259F29DFQ38881333-954D0FD8-B9F5-429B-B97B-36A1F08CB3BFQ38998392-1EA44F4B-0D41-40D2-9E19-873D2981888CQ39198568-D2096C17-8AB8-46AF-B938-42E7B5A93C8BQ39539756-4B33CC98-4377-4E75-ABE0-F92DAEB4716AQ39672622-64DDB7FC-A3A5-4D8C-BA71-B2FBA23E11C6Q41257562-4E5F30EF-F7E0-4EEB-819E-A4C88E088677Q41894042-04603F45-0302-4BAC-BA52-C4E862CA1B3EQ42959395-0B863070-B976-4E21-98F1-84398D4D8B97Q45366363-0FA20BAF-84B6-4305-8909-9E5CB9301088Q46864521-F3641276-D69E-4810-A625-93FF44D3F304Q47126732-029DBCF5-FE87-44A0-B380-89CE95CFFB19Q55417544-17E840F1-E7EF-4C21-B017-A158990B323CQ56838571-B47707EF-CF3A-4A0B-BD0D-BB1FD5609A79Q58135970-1A63950F-124A-4CE1-A6C3-927E7F11AE59Q59416200-2CF28FC4-4327-4CEA-AB27-FD2C76A6A18DQ59416217-43B209A6-C5A1-4179-ADE6-48D26E22B211Q59416223-9D7E6E0A-F72E-4850-AB1D-E03941889715
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
M Tagliamonte
@ast
M Tagliamonte
@en
M Tagliamonte
@es
M Tagliamonte
@nl
type
label
M Tagliamonte
@ast
M Tagliamonte
@en
M Tagliamonte
@es
M Tagliamonte
@nl
prefLabel
M Tagliamonte
@ast
M Tagliamonte
@en
M Tagliamonte
@es
M Tagliamonte
@nl
P106
P1153
8227203000
P31
P496
0000-0002-7167-4817